Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026

Lundbeck A/S today announced that new migraine clinical data will be presented at the European Academy of Neurology (EAN) Congress 2026, taking place 27–30 June in Geneva, Switzerland. The presentations will include new analyses of eptinezumab data, exploring outcomes that reflect the wider burden of chronic migraine beyond migraine frequency alone. Lundbeck will also present Phase IIb PROCEED primary data for bocunebart, an investigational treatment targeting pituitary adenylate cyclase-activating polypeptide (PACAP) in development for migraine prevention.

Together, these EAN presentations highlight Lundbeck’s dual focus in migraine: optimizing the use of current preventive treatment options while advancing future therapeutic approaches for people who continue to experience substantial disease burden.

Bocunebart data provide insight into PACAP pathway inhibition in migraine prevention
Among the highlights at EAN 2026 are data for bocunebart, a monoclonal antibody (mAb) designed to inhibit PACAP, a neuropeptide implicated in migraine pathophysiology distinct from anti-calcitonin gene-related peptide (aCGRP). PROCEED evaluated the efficacy, safety, dosing and route of administration of bocunebart in adults with migraine for whom one to four prior preventive treatments had failed.

“The presentation advances the evolving scientific understanding of PACAP pathway inhibition as a potential novel approach to migraine prevention for patients that continue to experience suboptimal disease control despite current preventive treatment options” said Andrew Blumenfeld MD, Cedars Sinai Los Angeles and presenter of the PROCEED findings at EAN 2026.

Eptinezumab data highlight patient-centered measures of migraine prevention
Lundbeck will also present new analyses from the Phase III SUNRISE and Phase IV RESOLUTION trials on eptinezumab, exploring treatment outcomes that reflect the wider clinical, functional and psychological burden of migraine.

Three presentations from the RESOLUTION trial will focus on adults living with chronic migraine and medication-overuse headache (MOH), a patient population in which migraine prevention is complicated by frequent headache, high acute medication use and substantial disease burden.

The analyses will examine treatment outcomes with eptinezumab across different European countries, patterns of acute medication use over time, and changes in symptoms of anxiety and depression that commonly accompany chronic migraine. In addition, the SUNRISE analysis will explore the impact of eptinezumab on workplace productivity and activity impairment in chronic migraine across regions in Asia and Europe.

“The burden of migraine extends well beyond the number of headache days. For many people living with migraine, the disease can affect multiple aspects of daily life, yet these impacts are not always fully captured in traditional measures of treatment benefit,” said Johan Luthman, Executive Vice President and Head of Research & Development at Lundbeck. “At EAN 2026, we are presenting data that reflect a broader view of migraine prevention, while also advancing scientific understanding of PACAP pathway inhibition through our investigational molecule bocunebart. Together, these presentations reflect Lundbeck’s commitment to advancing brain health in areas of unmet need.”

View details of Lundbeck presentations at EAN 2026 HERE.